Cambrex Sets Date for Special Meeting for Shareholders to Vote on Sale of Bioproducts and Biopharma
Stephanie LaFiura, Investor Relations Associate
EAST RUTHERFORD, NJ - Cambrex Corporation (NYSE: CBM, "Cambrex") today announced that a special meeting of shareholders will be held on February 5, 2007, to vote on the proposal to approve the sale of the Bioproducts and Biopharma subsidiaries (the "Bio Businesses") to Lonza Group AG ("Lonza"). Cambrex shareholders at the close of business on December 27, 2006, will be entitled to vote on the proposal. The Cambrex special meeting of shareholders will begin at 2:00 P.M. (local time) on Monday, February 5 at the Sheraton Meadowlands Hotel & Conference Center, Two Meadowlands Plaza, East Rutherford, New Jersey.
Cambrex Corporation has filed with the SEC and mailed to its stockholders a definitive proxy statement in connection with the special meeting of stockholders to approve the Bio Businesses transaction. The definitive proxy statement contains important information about Cambrex Corporation, the transaction and related matters. Investors and security holders are urged to read the definitive proxy statement carefully. Investors and security holders are able to obtain free copies of the definitive proxy statement and other documents filed with the SEC by Cambrex Corporation through the web site maintained by the SEC at www.sec.gov. In addition, investors and security holders may obtain free copies of the definitive proxy statement from Cambrex Corporation by contacting Peter Thauer, Senior Vice President, General Counsel and Secretary, at (201) 804-3000 or by calling Innisfree M&A Incorporated at (212) 750-5837.
Participants in the Solicitation
Cambrex Corporation and its executive officers and directors may be deemed, under SEC rules, to be participants in the solicitation of proxies from Cambrex Corporation's stockholders with respect to the proposed Bio Businesses transaction. Information regarding the executive officers and directors of Cambrex Corporation is set forth in the definitive proxy statement. More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities, holdings or otherwise, is also set forth in the definitive proxy statement.
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis, controlled substances and formulation of finished dosage form products. For more information, please visit www.cambrex.com.